EcoDrugPlus

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSACIG00000022053
Gene Symbol: F2R
1 Cross references
211 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSACIG00000006452
Gene Symbol: F2R
1 Cross references
260 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSACIG00000003782
Gene Symbol: F2R
1 Cross references
260 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSACIG00000006447
Gene Symbol: F2R
1 Cross references
260 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSACIG00000006433
Gene Symbol: F2R
2 Cross references
260 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSACIG00000003761
Gene Symbol: F2R
1 Cross references
260 Possible Orthologues:

Coagulation Factor Iiia

Ensembl ID : ENSACIG00000022649
Gene Symbol: F3A
1 Cross references
199 Possible Orthologues:

Coagulation Factor Vii, Like

Ensembl ID : ENSACIG00000009387
Gene Symbol: F7L
1 Cross references
203 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSACIG00000009625
Gene Symbol: F10
1 Cross references
238 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSACIG00000009568
Gene Symbol: F10
1 Cross references
239 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSACIG00000009472
Gene Symbol: F10
1 Cross references
239 Possible Orthologues:

Coiled-Coil Domain Containing 6a

Ensembl ID : ENSACIG00000006596
Gene Symbol: CCDC6A
1 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).